Helen C. Adams

US·SEC (Form 4)

Prometheus Biosciences, Inc.Immix Biopharma, Inc.

Total declarations

Companies

▲ Purchases (2 ops.)

€44k

▼ Sales (0 ops.)

—

Latest filing published 29 May 2026 for Immix Biopharma, Inc..

Filing timeline

BuySale

Helen C. Adams

Insider track record

Disclosed buys

Disclosed sells

Signal history

No signal scores available.

Closed purchases

Market purchases

Not enough history yet: 1 closed purchase, at least 2 are needed.

Purchases by company

Immix Biopharma, Inc. 1 purchase · last 14 Sept 2023

Since each purchase

Immix Biopharma, Inc.
Filed 14 Sept 2023 · 1136 days ago · €36k
-30.7%
Entry US$2.67 · Close at T+365 US$1.85

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

Helen C. Adams: trading record in brief

Filings by Helen C. Adams span 2 companies, the busiest being Immix Biopharma, Inc. and Prometheus Biosciences, Inc. Over a trading history stretching from 16 March 2021 to 22 May 2026, the count stands at 7 filings.

The open-market record is one-sided, with 2 purchases worth €44k and not one sale. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Besides market trades, the filings include 4 share grants.

Most recently, on 29 May 2026, the filings show a share grant in Immix Biopharma, Inc. The clock since the last published purchase (14 September 2023) now reads 1,136 days. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. Section 16 rules allow two business days to file each Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.